Events this week are the latest case in point.
A US Securities and Exchange Commission (SEC) administrative judge yesterday ruled that the Chinese joint ventures of the “Big Four” major global auditing firms should be banned from working for any US-listed Chinese companies for six months. The judge found that the four—Ernest & Young Hua Ming, KPMG Huazhen, Deloitte Touche Tohmatsu, and PwC Zhong Tian—had all engaged in deceptive accounting that violated the Sarbanes-Oxley Act.
However, you can rest easy over our China-based portfolio recommendations, such as AutoNavi Holdings (NSDQ: AMAP), China Petroleum & Chemical (NYSE: SNP) or Mindray Medical International (NYSE: MR). These major companies should remain untouched by the ruling.
Top 5 Forestry Companies To Own In Right Now: Medical Care Technologies Inc (MDCE)
Medical Care Technologies Inc., formerly AM Oil Resources & Technology Inc., incorporated on February 27, 2007, is a development-stage company. The Company is engaged in the development and maintenance of secure medical information systems used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates in three business segments: Medical Management Software Systems, Medi-Clinics and Pharmaceutical and Nutraceutical Products.
Medical Management Software Systems
The Company produces a range of medical management software systems, which could be used in a range of healthcare settings to electronically connect the healthcare industry with the consumer. It includes healthcare monitoring devices for glucose monitoring and cardiovascular monitoring and solutions, among others. The primary customers served by the software systems are hospitals and clinics, physicians��office practices, consumers and retail pharmacies, pharmaceutical companies and healthcare providers.
The Company have developed the Med-Suite Professional Practice Management information system. The Med-Suite is geared for usage by healthcare providers, such as physicians and nurses in hospitals, nursing homes and clinics. The e-management solution addresses the needs of healthcare providers to manage and communicate administrative and clinical data.
The second information systems product developed by the Company is the Tele-Health Suite. Tele-Health functions similarly to a hospital or doctor�� chart and is an interactive record to communicate patient data between healthcare providers and, healthcare providers and patients for treatment support, management and monitoring of the patient�� health.
The CareBox concept is a product designed for persons needing Tele-Health but who do not have access to the necessary computer hardware. The CareBox is a personal Internet communication de! vice that functions as the interface to the subscriber based network. The Company�� network would provide users access to telecommunication, tele-medicine applications and product access. The CareBox is engaged in the development of healthcare service delivery to the individual subscriber.
The CareBox system offers remote, real-time, audio-visual communication between patient and healthcare personnel. It offers a complete medical assessment, diagnosis, and treatment from a remote location. The CareBox processes on-site collections of physiological measurements and provides bi-directional audio-video communication.
The CareBox Bluetooth software requirements installed to mobile computing devices. It is compatible with iPhone, BlackBerry and other mobile cellular phone protocols. It enables wireless upload of personal medical information from medical and wellness monitoring devices.
Using the online facility, healthcare providers (doctors, nurses) could admit and assess patients, and subsequently create and revise individual healthcare plans. Attachments could be made to the CareBox, for monitoring blood-oxygen levels, temperature, blood pressure, pulse, as well as blood glucose levels. If readings are outside normal limits, the system would initiate a pre-programmed response and instruction for client intervention would be given. The system provides continuous monitoring at home for the clients, which serves to lengthen the period of time a person could live independently, while reducing the number of re-admissions to care facilities.
Retail Pharmacies and Retail Medical Clinics
The Company focuses to open professional, and convenience retail pharmacies and also retail medical clinics. Within the pharmacies, it focuses to have over the counter (OTC) drugs, nutritional supplements, herbal products, personal care products, family care products, as well as products, including consumable, seasonal and promotional items. The customers woul! d also ha! ve access to the medical software and hardware systems. It plans to open retail medical clinics, with a specific view to treating patients with telemedicine as well as a traditional treatment format.
Pharmaceutical and Nutraceutical Products
The Company plans to develop or source and sell pharmaceutical and nutraceutical products, and a range of other merchandise, including over-the-counter medicines, herbal products, personal care products, family care products in the planned Medi-Clinics, through the Website, retail pharmacies and through established sales and distribution channels in the People�� Republic of China. It would also offer private label products. Med-Suite, in concert with a person�� secure personal health record, would allow the medical professional to communicate pharmaceutical, administrative, clinical data in a cost-effective manner. The Company plans to use Med-Suite to provide marketing tools for pharmaceutical sales automation.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With Timios National Corp? According to various disclosures, at least one promoter expects to be compensated up to $140k to talk about Timios National Corp. However, Timios National Corp itself has been fairly quiet with news for the past several months except for financial filings. Probably the most recent relevant filing dates from September and is about an Asset Purchase Agreement with Adobe Title, LLC, whereby HOMS acquired all of the assets and properties of, and assumed certain liabilities, from the latter in consideration of $500,000 plus an earn-out equal to 7.25% of the Gross Revenue up to a maximum of $3,500,000 starting approximately six months from the date of the Agreement and ending on the forty-eighth monthly anniversary of such start date. A quick look at Timios National Corp�� financials reveals revenues of $6,810k (most recent reported quarter), $8,519k, $7,355k and $6,866k for the past four reported quarters along with a net loss of $120k (most recent reported quarter), net income of $329k and $66, and a net loss of $2,073k. At the end of September, Timios National Corp had $776k in cash to cover $3,661k in current liabilities and $6,700k in total liabilities. So its hard to explain the sudden share price decline last Friday.
Medical Care Technologies Inc (OTCMKTS: MDCE) Says Its Well Positioned to Profit From Health Care in Hong KongSmall cap Medical Care Technologies Inc, through joint ventures or Chinese subsidiaries, develops a network of family and children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class Chinese families. On Friday, Medical Care Technologies Inc sank 25% to $0.0012 for a market cap of $2,060 plus MDCE is up 1,100% over the past year and up 20% over the past five years according to Google Finance.
Top 5 Medical Stocks To Buy For 2014: Conmed Corp (CNMD)
CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.
Arthroscopy
The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.
Powered Surgical Instruments
Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.
The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.
The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.
Electrosurgery
The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.
Patient Care
The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.
Endosurgery
Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.
Endoscopic Technologies
The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.
The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.
The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.
Advisors' Opinion:- [By ovenerio]
In the medical devices business (83% of FY 13 sales), the company competes with good health care companies such as Johnson & Johnson (JNJ), C.R. Bard (BCR) and ConMed (CNMD).
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CONMED (Nasdaq: CNMD ) , whose recent revenue and earnings are plotted below.
Top 5 Medical Stocks To Buy For 2014: Portola Pharmaceuticals Inc (PTLA)
Portola Pharmaceuticals, Inc. (Portola), incorporated on September 2, 2003, is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology. The Company is advancing its three wholly owned programs using biomarker and genetic approaches.
Betrixaban
Portola's compound, betrixaban, is an oral, once-daily Factor Xa inhibitor being evaluated in the only biomarker-based Phase-III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's properties particularly suited to potentially demonstrate efficacy without increasing bleeding in this patient population.
Andexanet Alfa
Portola's second development candidate, andexanet alfa (PRT4445), has the potential to be a reversal agent to directly reverse the effects of Factor Xa inhibitors in patients who suffer a bleeding episode or who require emergency surgery. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb and Pfizer (Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO [rivaroxaban]), and Daiichi Sankyo (Savaysa [edoxaban]), while retaining all decision-making and commercial rights to the program.
Cerdulatinib (PRT2070) and PRT2607
Portola's third wholly owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways - spleen tyrosine kinase (Syk) and janus kinase (JAK). It is being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor.
Advisors' Opinion:- [By Todd Campbell]
That leads me to Medivation (NASDAQ: MDVN ) , Ophthotech (NASDAQ: OPHT ) , and Portola (NASDAQ: PTLA ) , three companies with important therapies that may very well be destined to become top sellers.
Top 5 Medical Stocks To Buy For 2014: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.
The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.
CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.
Advisors' Opinion:- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
- [By John Kell]
Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.
No comments:
Post a Comment